Roivant Sciences Ltd. (ROIV)
NASDAQ: ROIVHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
ROIV stock chart
Technical analysisKey statistics
All statistics- Market cap
- $25.10B
- EPS (TTM)
- -$0.53
- Dividend yield
- None
- 52-week range
- 15.90 – 42.50
- Day range
- 34.63 – 35.49
- Volume / Avg
- 5.74M / 7.04M
- Beta
- —
- Shares outstanding
- 722.32M
52-week range
ROIV stock today
Shares of Roivant Sciences (ROIV) finished lower on Oct 7 at $34.75, a drop of 2.20% or $0.78 per share, versus the S&P 500's 0.22% decline. At this level, ROIV sits in the middle of its 52-week range of $15.90 to $42.50: 18.2% below the high, set on Sep 8, 2026 and 118.6% above the low. ROIV is up 60.1% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 115.6%.
Roivant Sciences has posted a net loss over the last twelve months (EPS of -$0.53), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Roivant Sciences
Company profileRoivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases. The company's lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Matthew Gline
- Headquarters
- London
- Employees
- 721
- Website
- roivant.com
Financial highlights
Full financialsIn fiscal 2025, Roivant Sciences generated $8.3 million in revenue, down 71.6% from fiscal 2024, its first annual decline since 2024. Roivant Sciences reported a net loss of $299.8 million, compared with a loss of $172.0 million a year earlier. Operating margin was -6235.7%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Revenue | $8.26M | $29.05M | $32.71M | $31.53M | $55.29M |
| Growth | -71.57% | -11.19% | +3.75% | -42.97% | +132.34% |
| Net income | $-299.77M | $-171.98M | $4.35B | $-1.01B | $-845.26M |
| EPS (diluted) | $-0.54 | $-0.24 | $5.23 | $-1.42 | $-1.26 |
Analyst forecast
ForecastConsensus (13 analysts)
strong_buy
Avg. price target
$48.08+38.36%
- Strong buy 2
- Buy 10
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Q1 2026)
- Aug 6, 2026
- EPS actual vs est.
- $-0.26 vs —
ROIV news
All ROIV newsRoivant Sciences peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| UTHRUnited Therapeutics Corporation | 545.00 | +0.62% | $23.38B | vs ROIV |
| GMABGenmab A/S ADS | 36.65 | -3.04% | $22.54B | vs ROIV |
| INSMInsmed Incorporated | 101.74 | -3.32% | $22.22B | vs ROIV |
| ZTSZoetis Inc. Class A | 71.55 | +0.31% | $29.57B | vs ROIV |
| ALNYAlnylam Pharmaceuticals Inc. | 224.41 | +0.21% | $30.03B | vs ROIV |
| VTRSViatris Inc. | 17.49 | -0.29% | $20.09B | vs ROIV |
| RPRXRoyalty Pharma plc Class A | 56.76 | +0.57% | $32.80B | vs ROIV |
| ASNDAscendis Pharma A/S | 228.41 | +1.04% | $15.03B | vs ROIV |
Indexes, lists and sector
Roivant Sciences stock FAQ
What is Roivant Sciences's stock price today?
ROIV last traded at $34.75 as of Oct 7, 4:00 PM EDT, down 2.20% on the day. Prices are delayed at least 15 minutes.
Who is Roivant Sciences's CEO?
Mr. Matthew Gline is the chief executive officer of Roivant Sciences Ltd., which has about 721 employees.
What is the ROIV 52-week high?
The 52-week high for ROIV is $42.50 and the 52-week low is $15.90. The stock is currently 18.2% below its high.